Biodexa Pharmaceuticals Postpones Critical AGM Due to Lack of Quorum, Reschedules for June 30
BDRX is trading near its 52-week low of $2.86 (3.8% above the low).
Summary
Biodexa Pharmaceuticals Plc has postponed its Annual General Meeting, which was set to vote on a 1-for-10,000 reverse stock split, due to a lack of quorum. The meeting has been rescheduled for June 30, 2026.
Key Events · Corporate Governance and Compliance · BDRX
-
Annual General Meeting Postponed
The Annual General Meeting (AGM) scheduled for June 17, 2026, was adjourned due to a lack of quorum.
-
Reason for Postponement
The adjournment was specifically due to insufficient shareholder participation, indicating a lack of quorum.
-
Rescheduled Meeting Date
The AGM has been re-scheduled to take place on June 30, 2026, at the company's registered office.
-
Critical Vote Delayed
This postponement delays a crucial vote on a previously announced 1-for-10,000 reverse stock split, a significant corporate action for the company.
Analysis · BDRX · Life Sciences
The postponement of Biodexa Pharmaceuticals' Annual General Meeting, which was set to vote on a drastic 1-for-10,000 reverse stock split, is a significant governance concern for this micro-cap company. A lack of quorum suggests either shareholder apathy or difficulty in securing the necessary votes for a critical measure often used to avoid delisting or improve share price. This delay prolongs uncertainty regarding the company's ability to address its low share price and potentially meet listing requirements, especially as it trades near its 52-week low.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $2.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $2.86 to $66.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.